Eton Pharmaceuticals Gains FDA Approval for KHINDIVI

Eton Pharmaceuticals ( (ETON) ) has shared an update.

On May 28, 2025, Eton Pharmaceuticals announced the FDA approval of KHINDIVI, the first and only FDA-approved hydrocortisone oral solution for pediatric patients with adrenocortical insufficiency. This approval marks a significant advancement for patients and caregivers, offering a more precise and convenient dosing option. The commercial launch is expected in early June, with projected peak sales of KHINDIVI and ALKINDI SPRINKLE exceeding $50 million annually. The introduction of KHINDIVI is expected to enhance Eton’s market position in the rare disease treatment sector, providing a critical new tool for pediatric endocrinologists and improving treatment outcomes for patients.

The most recent analyst rating on (ETON) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Eton Pharmaceuticals stock, see the ETON Stock Forecast page.

Spark’s Take on ETON Stock

According to Spark, TipRanks’ AI Analyst, ETON is a Neutral.

Eton Pharmaceuticals’ stock shows a mixed outlook. Significant revenue growth and promising strategic initiatives are key strengths, while profitability challenges and an overbought technical profile are risks. Valuation metrics highlight the current losses typical for biotech firms in growth phases, and the positive earnings call suggests potential upside if strategic goals are met.

To see Spark’s full report on ETON stock, click here.

More about Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company is known for its products like KHINDIVI and ALKINDI SPRINKLE, which are aimed at addressing adrenocortical insufficiency in pediatric patients.

Average Trading Volume: 263,411

Technical Sentiment Signal: Buy

Current Market Cap: $537.4M

Learn more about ETON stock on TipRanks’ Stock Analysis page.